TRP_1170x120_3-8-19

Anne Whitaker

Valeant makes changes to executive team

Valeant makes changes to executive team

LAVAL, Quebec — Valeant Pharmaceuticals International Inc. has instituted a series of leadership and organizational changes, including an expansion of its executive committee and the duties of some senior executives. Valeant said Christina Ackermann has joined the company as executive vice president and general counsel of Valeant, succeeding Robert Chai-Onn, who will be leaving Valeant

Valeant to buy Sprout Pharmaceuticals for $1 billion

Valeant to buy Sprout Pharmaceuticals for $1 billion

LAVAL, Quebec — Valeant Pharmaceuticals International Inc. plans to acquire Sprout Pharmaceuticals Inc., the maker of a just-approved drug for sexual desire disorder in women, for about $1 billion in cash. Valeant said Thursday that it expects to close the deal in the third quarter of this year, pending customary closing conditions and regulatory approval.